[Research status and future direction of irreversible EGFR-TKI in non-small cell lung cancer]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are crucial for EGFR-mutant non-small cell lung cancer (NSCLC).
• First and second-generation EGFR-TKI exhibit limitations due to acquired resistance, notably the T790M mutation.
• Irreversible EGFR-TKI represent a significant advancement in overcoming acquired resistance.

Purpose of the Study:

• To systematically review the mechanism of action of irreversible EGFR-TKI.
• To summarize the clinical research progress and future directions of irreversible EGFR-TKI.
• To explore strategies for overcoming drug resistance, combination treatments, and biomarker-guided personalized therapy.

Main Methods:

• Systematic literature review.
• Analysis of preclinical and clinical studies on irreversible EGFR-TKI.
• Evaluation of resistance mechanisms and therapeutic strategies.

Main Results:

• Irreversible EGFR-TKI utilize a covalent binding mechanism to enhance inhibition of drug-resistant mutations.
• These agents have demonstrated potential to prolong patient survival in EGFR-mutant NSCLC.
• Combination therapies and personalized approaches are emerging as key strategies.

Conclusions:

• Irreversible EGFR-TKI are a promising therapeutic option for overcoming resistance in EGFR-mutant NSCLC.
• Further research into combination treatments and biomarker-guided therapy is warranted.
• These agents hold significant potential for improving clinical practice and patient outcomes.